🔎 Trials Near Me

Home › Myelodysplastic Syndromes

Myelodysplastic Syndromes clinical trials recruiting in the U.S.

157 studies for Myelodysplastic Syndromes are recruiting participants at sites across the United States.

Myelodysplastic Syndromes (MDS) are rare. They are sometimes found during a routine blood test. Learn symptoms, risk factors, and treatment options.

Cities with the most studies

By state

Recently updated studies

Natural History of Trisomy 8-Associated Autoinflammatory Disease (TRIAD) and Related Disorders

RecruitingObservational study
1 Day – 99 Years · All sexes · Updated Oct 2, 2026 · NCT07683104

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

RecruitingPhase 1
Ages 12 to 78 · All sexes · Updated Sep 29, 2026 · NCT03802695

CHIP/CCUS Natural History Protocol

RecruitingObservational study
Ages 18 to 99 · All sexes · Updated Sep 28, 2026 · NCT04102423

Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT05320198

Natural History Study of GATA2 Deficiency and Related Disorders

RecruitingObservational studyHealthy volunteers welcome
Ages 2 to 100 · All sexes · Updated Sep 22, 2026 · NCT01905826

Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT04282187

Collection of Tissue Samples for Cancer Research

RecruitingObservational study
2 Months · All sexes · Updated Sep 16, 2026 · NCT00900198

Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood

RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT06904482

Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT03471260

Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation

RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT03683433

A Study of BGB-11417 in Participants With Myeloid Malignancies

RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT04771130

From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.